VolitionRx Limited (Namur) celebrated the company's recent announcement of a CE mark for its Nu.QTM Colorectal Cancer Screening Triage Test by ringing the closing bell at the New York Stock Exchange on Monday, March 13, 2017 at 4 p.m. U.S. Eastern Daylight Time. Volition received CE Marking on the Nu.QTM Colorectal Cancer Screening Triage Test in December 2016 and is currently marketing this novel blood test in Europe.
The event was preceded earlier that day by a more traditional bell ringing ceremony at Trinity Church Wall Street led by Volition's Chairman, Dr. Martin Faulkes. Dr. Faulkes, a keen bell ringer, donated and installed the 12 bells at Trinity Church Wall Street in 2006.
Speaking about the celebration, Cameron Reynolds, CEO of Volition said: "We are very pleased to be at the NYSE at this very exciting time for Volition. We are coming to market with a diagnostic cancer test that we believe meets a pressing and immediate need in many European countries. Being able to offer healthcare systems a simple and easy to use blood test, which may be used to triage FIT positive populations for colorectal cancer, has the potential to make a significant and positive difference for their national colorectal cancer screening programs."
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid, an indication that disease is present.
Volition's research and development activities are currently centered in Belgium (Namur), with additional offices in London, New York, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
To watch the video of the event: https://livestream.com/NYSE/VolitionRxLimited/videos/151706797
